Aevi Genomic Medicine, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aevi Genomic Medicine, Inc.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Medgenics Medical Israel Ltd.
- neuroFix Therapeutics, LLC
- Medgenics Inc.